Bio-Rad Laboratories’ Post

This paper presents an improved anion exchange analytical method . It delivers enhanced separation of full AAV capsids from other common product-related impurities such as aggregates, and empty, partially filled, high density, or damaged capsids. The improved anion exchange analytical method has been shown to be applicable for different AAV serotypes.

𝗡𝗲𝘄 𝗪𝗲𝗯𝗶𝗻𝗮𝗿: 𝗩𝗶𝗿𝗮𝗹 𝗩𝗲𝗰𝘁𝗼𝗿 𝗜𝗻𝘁𝗲𝗴𝗿𝗶𝘁𝘆 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 – 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁. Missed it live? We've got you covered! Dive into the latest innovations and strategies shaping viral vector integrity and their critical role in advancing gene therapy development. Whether you're in R&D or scaling for commercialization, this is a must-watch for staying ahead in the rapidly evolving CGT space. Watch now: https://lnkd.in/edBiimCN #CDMO #CGT #genetherapy #viralvectors

Tiny tools for big breakthroughs! Bio-Rad Laboratories’s VeriCheck ddPCR Kits are here to supercharge AAV gene therapy research with precise, reliable results. Why settle for "meh" accuracy when you can have ddPCR precision? These kits simplify workflows while giving you the data confidence to go from "What if?" to "Look what we did!" Ready to expand your AAV research horizons? Check out the details: https://bit.ly/4jC2MbV

InspiroGene by McKesson’s inaugural 2024 Cell and Gene Therapy Report highlights both the progress and pressing challenges in the CGT landscape. With a record number of CGTs approved in 2023, the field is expanding beyond oncology, with therapies for neurological, cardiovascular, and metabolic conditions making up a growing portion of the pipeline. While most oncologists view CGTs as a major innovation, three in five remain cautious, citing concerns over safety, affordability, and patient preference. As investor interest cools, overcoming barriers in manufacturing, clinician training, and patient access will be essential for CGT’s growth. Check out the full report: https://lnkd.in/eMc8FNuf #Clora #celltherapy #genetherapy #oncology #futureofmedicine #geneticmedicine

Are you interested in learning more about the existing patient referral pathways for #AdvancedTherapies in the UK and how these can be improved? ➡️ https://ow.ly/qf9x50UqyVP Take a look at our webinar on 'Evaluation of the Patient Referral Pathways for Gene Therapy and CAR-T in the UK' which provides an overview of two projects that assessed patient referral pathways for different advanced therapies and the resulting best practice recommendations. Watch it here ☝️ #ATTCnetwork #ATMPs #PatientAccess

The Advanced Therapy Treatment Centre (ATTC) network, coordinated by the Cell and Gene Therapy Catapult, has produced a webinar which focuses on #ATMP patient referral pathways in the UK and how these can be improved. Titled 'Evaluation of the Patient Referral Pathways for Gene Therapy and CAR-T in the UK, the webinar provides an overview of two projects that assessed patient referral pathways for different #AdvancedTherapies and the resulting best practice recommendations. Watch the recording: https://lnkd.in/eYEAghyw #ATTCnetwork #PatientAccess

Curious turn of events for Sarepta / Roche - DMD gene therapy appears to exhibit positive benefits after 2 years of continued monitoring. Recall the controversial decision of Peter Marks made to approve Elivedys despite missing primary endpoint in initial phase 3 results. I write this while I am baking a loaf of sourdough this morning. Perhaps clinical read-out at too early a time point is bread half-baked. DMD is a serious, devastating disease, positive outcomes are greatly needed. History of DMD gene therapy trials recently described here - https://lnkd.in/d6w-bUiU and Courtney Rice's commentary here -

Does your organization have new goals and initiatives for 2025? Here is a great way to get your year started right!

McKesson issued its 2024 Cell and Gene Therapy report last week. One theme was the idea that limited Centers of Excellence / Qualified Treatment Centers leads to limited awareness and access, especially in the onology space. Knowing that every report serves its own agenda, it's worth a thumb through (you know where to look for access - they want your data before you can download and I don't want to steal their thunder by posting whole report). #cgt #genetherapy #atmp #celltherapy #CAR-T

We guide you towards an oasis of reliable cell and gene therapy (CGT) analytics. Where assay translation from analytical development to quality control (QC), potency assay development, and assay validation become straightforward. #MiltenyiBiotec #drivingCGT Learn more: https://ow.ly/6ROV50RfVpu